Press Release

Glythera launches UK government funded project to develop safer and more efficacious ADCs for the treatment of difficult-to-treat tumours

- Development of proprietary next generation ADC portfolio -  - Secures £1m in grant funding - Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, today announces the launch of a £1 million Innovate UK grant-funded project to develop next-generation ADCs for difficult-to-treat tumours using Glythera’s proprietary non-maleimide conjugation platform, PermaLink®, in combination with its portfolio of novel toxins and antibodies. ADCs are an emerging class of targeted therapeutics in the fight against cancer. By combining the…

Read more>>

Glythera demonstrates improved activity and safety of PermaLink®-based ADCs

Glythera demonstrates improved activity and safety of PermaLink®-based ADCs    Appoints Scientific Advisory Board   -Significantly improved tolerability of ADCs incorporating highly potent toxins- - Efficacy outperforms industry-standard ADC technology – -Development of proprietary ADC pipeline supported by key industry appointments to SAB-   Glythera Limited (‘Glythera’), the next generation Antibody Drug Conjugate (‘ADC’) development company, today provides further evidence that PermaLink®, its proprietary non-maleimide conjugation platform, enables the production of ADCs with potentially greater clinical utility than current industry-standard…

Read more>>

Avacta and Glythera announce collaboration to develop novel, potentially highly potent, drug class

The collaboration will evaluate the use of Avacta’s Affimer technology in combination with Glythera’s PermaLink conjugation chemistry Generation of a new class of highly targeted bio-therapeutics as a potentially superior alternative to antibody drug conjugates (ADCs), a market estimated to be worth $10bn by 2024 Avacta Group plc (AIM: AVCT) (“Avacta” or “the Group”) the developer of Affimer® biotherapeutics and research reagents and Glythera Limited the developer of advanced, stable conjugation chemistries and novel, ultra-potent toxin payloads, today announce that…

Read more>>